SYDNEY — Shares of PYC Therapeutics fell more than 10 percent on Tuesday, trading at $2.14, down 25 cents, or 10.46 percent, as the Australian RNA-therapy developer continued a pullback from its September high ahead of a data presentation on its lead kidney-disease candidate.

The stock's 52-week range is about $1.05 to $2.93. It closed Monday near $2.39. The market value is roughly $2.4 billion Australian dollars on about 983.5 million shares. The shares have more than doubled over the past year even after the recent decline. No new clinical result was released on Tuesday.

On Oct. 7 the company said it would present exploratory efficacy data from single-dose Phase 1a/1b studies of PYC-003 in patients........

© International Business Times